Search Results - TherapeuticArea+%3e+Immunology

202 Results

Sort By:

Immunosuppressive Exosomes for Treating Autoimmune Diseases

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases. This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Minkyung Kang, Charles Egwuagu

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Carriers/Adjuvants, TherapeuticArea > Immunology, TherapeuticArea > Neurology, TherapeuticArea > Ophthalmology

Calcineurin Inhibitor-Antibody Conjugates for Targeted Treatment of Th17 Driven Inflammatory Diseases

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of calcineurin inhibitor-antibody conjugates aimed at treating Th17 driven inflammatory diseases. This technology includes calcineurin inhibitor-antibody conjugates designed for the targeted treatment of Th17 driven inflammatory diseases, such...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Andrew Dick, Lauren Schewitz Bowers, Robert Nussenblatt, Lai Wei, Igal Gery, Richard Lee

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Ophthalmology, TherapeuticArea > Neurology

AI Based Workflow for Single Cell Analysis

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations. This technology includes SCassist, an innovative...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Rachel Caspi, Vijayaraj Nagarajan

Keywords(s):

A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...

Published: 5/14/2026 | Updated: 5/14/2026 | Inventor(s): Patrick Duffy, Jonathan Renn

Keywords(s):

Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy

Summary: Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees...

Published: 5/14/2026 | Updated: 5/14/2026 | Inventor(s): Steven Rosenberg, Sanghyun (Peter) Kim

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions

Summary: Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used...

Published: 5/12/2026 | Updated: 9/29/2025 | Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan, Yeon-Ji Park

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics

Combination PDL1 and TGF Beta Blockade in Patients with HPV-Associated Malignancies

Summary: The National Cancer Institute (NCI) seeks collaborations and licensees for a method to block PD-L1 and TGF-beta for the treatment of HPV-associated malignancies. Description of Technology: Advanced or relapsed human papillomavirus (HPV)-associated cancers are incurable and many of these diseases do not have a standard second line therapy....

Published: 11/26/2025 | Updated: 9/29/2025 | Inventor(s): Julius Strauss, James Gulley, Christian Hinrichs

Keywords(s):

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein

Summary: The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many...

Published: 9/29/2025 | Updated: 9/29/2025 | Inventor(s): Jeffrey Schlom, Kwong-Yok Tsang

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. Description...

Published: 9/29/2025 | Updated: 9/29/2025 | Inventor(s): Jeffrey Schlom, Duane Hamilton, Claudia Palena, Renee Donahue

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

Innovative Antibody Conjugates for Targeted Therapy

This advanced technology introduces innovative antibody conjugates that redefine the possibilities of targeted therapy. By coupling therapeutic agents to engineered antibodies with highly specific binding sites, these conjugates deliver treatments directly to diseased cells while sparing healthy tissues. The result is a powerful increase in treatment...

Published: 1/2/2026 | Updated: 9/22/2025 | Inventor(s): Nicole Morgan, Paniz Rezvan Sangsari, Parinaz Fathi, Kaitlyn Sadtler

Keywords(s):

Category(s): Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

1 2 3 4 5 6 7 8 9 10 ...